More treatment options means greater hope for people living with Parkinson's disease

Living with Parkinson’s disease (PD) can be daunting for many reasons, especially since there currently is no known cure for PD. However, there are medicines, surgical interventions and other innovative treatments that may help patients manage some of the symptoms. Promising strides are currently being made in PD research every day. By participating in a clinical trial, people living with advanced Parkinson’s disease help researchers gain invaluable insight to better understand this condition, and offer renewed hope for patients everywhere.

See If You Qualify

How It Works

Starting the process only takes a few minutes

Complete The Survey

Answer some brief, easy questions and we’ll let you know whether you may be eligible to participate in the study.

Schedule An Appointment

If you qualify, the next step is speaking with a team member. Just find 10-15 free minutes in your day and we’ll get you connected.

Speak To A Team Member

Our dedicated specialists understand your situation and will listen, answer any questions, and address your concerns. We’re here to help.

See If You Qualify

Understanding Parkinson’s disease

What is Parkinson’s Disease (PD)?

Parkinson’s disease is a neurodegenerative disorder of the brain which causes uncontrolled movements such as shaking (tremors), stiffness, slumped posture, and challenges to balance and coordination. Symptoms may begin gradually, but PD’s effects on the central nervous system are chronic (meaning persistent), as well as progressive (meaning they worsen over time). In addition to motor-related symptoms, patients with PD also experience non-motor symptoms including cognitive impairment, mood/behavioral issues, sleep disorders, and even GI disruptions like constipation, which can significantly impair quality of life.¹

Treatment Options

Although there is no cure for Parkinson’s, there are medicines, surgical interventions and other treatments that may help patients manage some of the symptoms. Currently, the main therapy for Parkinson’s disease treatment, levodopa, promotes the production of dopamine in the nerve cells to replenish the brain’s dwindling supply. Though taken in tandem with other drugs to help manage some of its side effects, a long-term, unwanted effect of remaining on levodopa for patients can be dyskinesia, or involuntary, writhing, erratic movements of the face, arms, legs or torso. A hallmark of Parkinson’s is patients experiencing ON and OFF periods, also called motor fluctuations. “ON” periods are times when the medication is working well, and symptoms are less noticeable. “OFF” periods are instances when the medication’s effects wear off, and symptoms return or worsen. Some PD treatments, like this study, are focused on decreasing patients’ OFF periods in an attempt to help them better navigate their daily lives.

What We Hope To Do

There is a real need for a Parkinson’s disease (PD) treatment option that doesn’t solely involve prolonged reliance on levodopa. That’s why the purpose of this clinical study is to evaluate the effectiveness of decreasing, or putting the brakes on, of a receptor found in the “indirect pathway” of the brain, as opposed to ramping up dopamine levels. During PD, this receptor becomes overstimulated, and is responsible for much of the motor and non-motor issues associated with the disease. It is our hope that this alternative approach, if successful, may potentially afford patients improvement on their motor and non-motor symptoms, increase the ON time where patients’ symptoms are being managed, and provide them with an improved quality of life.

What is Parkinson’s Disease (PD)?

Parkinson’s disease is a neurodegenerative disorder of the brain which causes uncontrolled movements such as shaking (tremors), stiffness, slumped posture, and challenges to balance and coordination.

Symptoms may begin gradually, but PD’s effects on the central nervous system are chronic (meaning persistent), as well as progressive (meaning they worsen over time). In addition to motor-related symptoms, patients with PD also experience non-motor symptoms including cognitive impairment, mood/behavioral issues, sleep disorders, and even GI disruptions like constipation, which can significantly impair quality of life.¹

Treatment Options

Although there is no cure for Parkinson’s, there are medicines, surgical interventions and other treatments that may help patients manage some of the symptoms.

Currently, the main therapy for Parkinson’s disease treatment, levodopa, promotes the production of dopamine in the nerve cells to replenish the brain’s dwindling supply. Though taken in tandem with other drugs to help manage some of its side effects, a long-term, unwanted effect of remaining on levodopa for patients can be dyskinesia, or involuntary, writhing, erratic movements of the face, arms, legs or torso. A hallmark of Parkinson’s is patients experiencing ON and OFF periods, also called motor fluctuations. “ON” periods are times when the medication is working well, and symptoms are less noticeable. “OFF” periods are instances when the medication’s effects wear off, and symptoms return or worsen. Some PD treatments, like this study, are focused on decreasing patients’ OFF periods in an attempt to help them better navigate their daily lives.

What We Hope To Do

There is a real need for a Parkinson’s disease (PD) treatment option that doesn’t solely involve prolonged reliance on levodopa.

That’s why the purpose of this clinical study is to evaluate the effectiveness of decreasing, or putting the brakes on, of a receptor found in the “indirect pathway” of the brain, as opposed to ramping up dopamine levels. During PD, this receptor becomes overstimulated, and is responsible for much of the motor and non-motor issues associated with the disease. It is our hope that this alternative approach, if successful, may potentially afford patients improvement on their motor and non-motor symptoms, increase the ON time where patients’ symptoms are being managed, and provide them with an improved quality of life.

Who Can Participate?

Here are the qualifications participants need to meet in order to join the Parkinson’s study.

Be at least 30 years old
Have a confirmed diagnosis of Parkinson’s disease (PD)
Experience clearly defined ON, OFF, and dyskinetic periods throughout the day where PD medication is either managing symptoms or waning
Be on a stable dose of PD medication for at least 30 days; MAO-B inhibitors (such as selegiline, rasagiline, safinamide) must be stable for at least 12 weeks
Are able to freely move about, with or without the use of an assistive device

Learn more about our participation criteria to see if you may be a good fit for this trial.

See If You Qualify

Frequently Asked Questions

What are the symptoms of Parkinson’s disease?

Signs may include:³

Tremors, or involuntary shaking, in hands, arms, legs, head or jaw
Stiffness or contracting of the muscles that may cause pain or limit your range of motion
Slowed movement, called bradykinesia, when walking, getting up out of a chair, etc.
Impaired balance and coordination, sometimes leading to falls
Stooped or slumped posture
Difficulty with speech or handwriting
Challenges with unconscious movements like blinking, smiling, swinging of arms while walking

3. Source: https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/symptoms-causes/syc-20376055

Who may be a good candidate to apply for this Parkinson’s study?

You should consider applying for the study if you or a loved one:

Are at least 30 years old
Have a confirmed diagnosis of Parkinson’s disease (PD)
Experience clearly defined ON, OFF, and dyskinetic periods throughout the day where PD medication is either managing symptoms or waning
Have been on a stable dose of PD medication for at least 30 days, or a stable dose of MAO-B inhibitors for at least 12 weeks
Are able to freely move about, with or without the use of an assistive device

What will happen during the study?

This is a randomized Phase 3 clinical research study, also called a clinical trial, examining a treatment called CVN424 (Solengepras) in patients with Parkinson’s disease (PD) with motor complications. The purpose of this study is to measure CVN424’s (Solengepras) effect both on participants’ motor as well as non-motor functions, as compared to placebo (which contains no active medication). The study will last around 20 weeks, including screening, treatment, and follow-up periods, with the potential for an open-label extension (OLE) study in the future . Throughout this clinical study, it is our goal that participants will enjoy a safe, caring environment, and will be treated with compassion and respect.

Are there any costs to participate in this study?

No, there is no cost to participate. Qualified participants will receive all study-related care and study medication at no cost, and compensation for time and travel may be available.

Still have questions?

Contact us anytime at help@clinicalenrollment.com

Visit The FAQ Page